2269 Stock Overview
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$13.32 |
52 Week High | HK$54.70 |
52 Week Low | HK$12.88 |
Beta | 0.62 |
1 Month Change | -9.76% |
3 Month Change | -54.23% |
1 Year Change | -75.13% |
3 Year Change | -87.62% |
5 Year Change | -49.80% |
Change since IPO | 41.45% |
Recent News & Updates
Recent updates
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease
Aug 02Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Jun 29What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
May 16Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today
May 03Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Apr 21An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 42% Undervalued
Mar 26Why We're Not Concerned Yet About WuXi Biologics (Cayman) Inc.'s (HKG:2269) 30% Share Price Plunge
Feb 09Shareholder Returns
2269 | HK Life Sciences | HK Market | |
---|---|---|---|
7D | -7.1% | -11.1% | -1.9% |
1Y | -75.1% | -70.1% | -16.4% |
Return vs Industry: 2269 underperformed the Hong Kong Life Sciences industry which returned -70.1% over the past year.
Return vs Market: 2269 underperformed the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
2269 volatility | |
---|---|
2269 Average Weekly Movement | 15.0% |
Life Sciences Industry Average Movement | 10.8% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.8% |
10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 2269's share price has been volatile over the past 3 months.
Volatility Over Time: 2269's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 12,740 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
2269 fundamental statistics | |
---|---|
Market cap | HK$54.37b |
Earnings (TTM) | HK$3.68b |
Revenue (TTM) | HK$18.43b |
15.1x
P/E Ratio3.0x
P/S RatioIs 2269 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2269 income statement (TTM) | |
---|---|
Revenue | CN¥17.03b |
Cost of Revenue | CN¥10.21b |
Gross Profit | CN¥6.83b |
Other Expenses | CN¥3.43b |
Earnings | CN¥3.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.82 |
Gross Margin | 40.08% |
Net Profit Margin | 19.96% |
Debt/Equity Ratio | 4.9% |
How did 2269 perform over the long term?
See historical performance and comparison